Edvan de Queiroz Crusoé

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 380 citations

Medicine, Pharmacology, Pharmacotherapy +12

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

Enrique M. Ocio, David Vilanova, Peter Atadja et al. · Haematologica · 2009 · 156 citations · Full text

Medicine, Oncology, Pharmacology +16

Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice

Artur Jurczyszyn, Norbert Grząśko, Alessandro Gozzetti et al. · American Journal of Hematology · 2016 · 141 citations · Full text

Medicine, Hematology, Oncology +14

Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

Antonio García-Gómez, Enrique M. Ocio, Edvan de Queiroz Crusoé et al. · PLoS ONE · 2012 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Observational study of multiple myeloma in Latin America

Vânia Hungria, Ângelo Maiolino, Gracia Martınez et al. · Annals of Hematology · 2016 · 58 citations

Medicine, Hematology, Oncology +16